PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Phathom Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.01+0.09 (+1.30%)
Close on Oct 19, 2026
- Market cap
- $587.07M
- P/E (TTM)
- –
- Dividend yield
- –
Phathom Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $567.12M | $166.30M |
| Enterprise Value | $549.23M | $88.19M |
| PS Ratio | 2.37 | 3.65 |
Enterprise value
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.29 | 2.51 |
Income (trailing twelve months)
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $239.66M | $58.34M |
| Gross Profit | $198.73M | $105.94M |
| Operating Income | -$40.64M | -$21.40M |
| Net Income | -$99.07M | -$22.46M |
| EBITDA | -$40.13M | -$16.91M |
| EPS (Diluted) | -$1.28 | -$0.83 |
Margins
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 82.9% | 52.9% |
| Operating Margin | -17.0% | -44.0% |
| Profit Margin | -41.3% | -40.2% |
| EBITDA Margin | -16.7% | -30.2% |
| FCF Margin | -15.4% | -9.27% |
Returns
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -34.3% | -40.9% |
| Return on Capital Employed (ROCE) | -23.5% | -38.1% |
Growth
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 110.2% | 5.96% |
Balance sheet
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $182.48M | $61.43M |
| Total Debt | $164.59M | $118.52M |
| Net Cash (Debt) | $17.89M | $15.35M |
| Net Cash Per Share | $0.22 | $0.66 |
| Equity (Book Value) | -$344.27M | $49.09M |
| Book Value Per Share | -$4.26 | $1.37 |
| Tangible Book Value | -$344.27M | $23.52M |
| Working Capital | $142.14M | $76.81M |
Financial position
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 1.92 | 3.34 |
| Quick Ratio | 1.82 | 2.44 |
| Interest Coverage | -0.64 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.69M | -$12.35M |
| Capital Expenditures | -$219.00K | -$1.08M |
| Free Cash Flow | -$36.91M | -$20.22M |
| FCF Per Share | -$0.46 | -$0.42 |
Efficiency
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.83 | 0.39 |
| Inventory Turnover | 7.35 | 2.70 |
| Revenue Per Employee | $645.99K | $404.87K |
| Profits Per Employee | -$267.04K | -$703.34K |
| Employee Count | 371 | 74 |
Dividends and yields
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -17.5% | -23.3% |
| FCF Yield | -6.51% | -8.72% |
Shares
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 80,900,900 | 58,127,000 |
| Shares Change (YoY) | 11.7% | 10.9% |
| Shares Change (QoQ) | 0.79% | 0.54% |
| Float | 71,031,400 | 49,136,700 |
| Shares Held by Insiders | 12.2% | 11.6% |
| Shares Held by Institutions | 89.1% | 59.4% |
Scores
| Measure | Phathom Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -5.21 | -0.22 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -1.38 | -2.62 |
Calculated by StockData from Phathom Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.